- CHF10.4M ($104M) of cash and cash equivalents September 30th, 2022
- Janssen led the phase 2 study ADX71149 in epilepsy on the way to graduatione part 1 in Q1 2023
Ad hoc notification acc. 53LR
Geneva, Switzerland, November 112022 – Appendix therapeutics ADXNa clinical-stage pharmaceutical company pioneering the discovery and development of drugs based on allosteric modulation, today released its financial results for the third quarter ended September 30, 2022 and provided a company update.
“The extension of our strategic collaboration with Indivior and the recent financing from Armistice Capital positions us to execute on our strategic priorities, including pursuing additional collaboration agreements across our portfolio,” said Tim Dyer, CEO of Addex. “Additionally, we look forward to completing Part 1 of the ADX71149 Epilepsy Phase 2 study in Q1 2023 and continue to evaluate the way forward for dipraglurant in a number of interesting disease areas, in parallel with discussions with potential strategic partners.”
Q3 2022 Operational Highlights:
- ADX71149 Epilepsy Phase 2 Study On Track To Complete Part 1 In Q1 2023
- GABAB PAM’s Strategic Partnership Extended with Indivior in Substance Use Disorders – Multiple Drug Candidates in Late Stages of Clinical Candidate Selection Phase
- GABAB PAM CMT1A, chronic cough and pain program profiling multiple drug candidates
- The mGlu7 NAM program for stress-related disorders delivered an IND-eligible study-ready drug candidate
- mGlu2…
